Glaucoma is a major cause of blindness worldwide. Glaucomatous eyes are subjected to an accelerated aging process due to an overproduction of advanced glycation end-products (AGEs) as well as its cognate receptor RAGE. Several topical antiglaucoma drugs and relative conservative molecules, including -blockers, prostaglandin derivatives and benzalkonium chloride as preservative, are frequently used in the treatment of glaucoma. However, no data focusing on the effects of topical antiglaucoma therapies on the levels of AGEs exists. Therefore, we aimed to determine whether the AGEs production in the conjunctival sac fluid was influenced by topical antiglaucoma therapies. AGEs were measured by direct spectrofluorimetric detection in the conjunctival sac fluid of glaucoma patients, treated with different topical therapies, and controls. The fluorescent intensity was expressed in AGE Units (AGE U). The levels of AGE were higher in patients treated with -blockers with respect to both control and the prostaglandin groups (for both comparisons, P<0.05). Patients treated with prostaglandin had comparable levels to the controls. None difference was observed between -blockers and -blockers in association with other drugs nor between the different kinds of prostaglandin analogues. Previously, it has been observed that prostaglandins have antioxidative properties reducing the ROS production. Since the ROS and AGEs are strictly interconnected, the effect we observed here might be due to a lower ROS production which in turn affects the levels of AGEs. In conclusion, the treatment with prostaglandins can have two positive effects: lowering of the IOP and decrease the AGEs production in the conjunctival sac.
Antiglaucoma drops influence the production of advanced glycation end-products (AGEs) in the conjunctival sac fluid of glaucoma patients
MANFRINATO, Maria Cristina;TRENTINI, Alessandro;ROMANI, Arianna;CERVELLATI, Carlo;DALLOCCHIO, Franco Pasquale Filippo;PERRI, Paolo;SORRENTINO, Francesco Saverio;LAMBERTI, Giuseppe;SEBASTIANI, Adolfo;BELLINI, Tiziana
2014
Abstract
Glaucoma is a major cause of blindness worldwide. Glaucomatous eyes are subjected to an accelerated aging process due to an overproduction of advanced glycation end-products (AGEs) as well as its cognate receptor RAGE. Several topical antiglaucoma drugs and relative conservative molecules, including -blockers, prostaglandin derivatives and benzalkonium chloride as preservative, are frequently used in the treatment of glaucoma. However, no data focusing on the effects of topical antiglaucoma therapies on the levels of AGEs exists. Therefore, we aimed to determine whether the AGEs production in the conjunctival sac fluid was influenced by topical antiglaucoma therapies. AGEs were measured by direct spectrofluorimetric detection in the conjunctival sac fluid of glaucoma patients, treated with different topical therapies, and controls. The fluorescent intensity was expressed in AGE Units (AGE U). The levels of AGE were higher in patients treated with -blockers with respect to both control and the prostaglandin groups (for both comparisons, P<0.05). Patients treated with prostaglandin had comparable levels to the controls. None difference was observed between -blockers and -blockers in association with other drugs nor between the different kinds of prostaglandin analogues. Previously, it has been observed that prostaglandins have antioxidative properties reducing the ROS production. Since the ROS and AGEs are strictly interconnected, the effect we observed here might be due to a lower ROS production which in turn affects the levels of AGEs. In conclusion, the treatment with prostaglandins can have two positive effects: lowering of the IOP and decrease the AGEs production in the conjunctival sac.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
